Monitoring & Evaluation of RNTCP

Slides:



Advertisements
Similar presentations
Stop TB Strategy Planning Frameworks Mukund Uplekar TB Strategy, Operations and Health Systems, Stop TB Department, WHO.
Advertisements

DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Planning in line with the Stop TB Strategy and the Global Plan to Stop TB, Dr Win Maung Programme Manager National Tuberculosis Programme Ministry.
From DOTS to the Stop TB Strategy Building on Achievements for Future Planning Stop TB Partnership Symposium at the 37 th UNION World Conference on TB.
Improving diagnosis TB laboratory strengthening.
World Health Organization TB Case Definitions
Accelerating PMDT scale up in Ethiopia
GUIDELINES & TOOLS for HOSPITAL DOTS LINKAGE (HDL)
Introduction Thailand one of 22 countries which contain 80% of the estimated tuberculosis (TB) cases in the world. Thailand ranks 17 th among the 22 high-burden.
Monitoring and Evaluation: Tuberculosis Control Programs
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs Using the Compendium to Plan for Monitoring and Evaluation of NTPs.
Introduction to Monitoring and Evaluation for National TB Programs 20 September 2005.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Indicators, Data Sources, and Data Quality for TB M&E
National Tuberculosis Control Program
1 Module PLANNING AND ORGANIZING EXTERNAL QUALITY ASSESSMENT.
NTF Presentations for RNTCP Sensitization First edition 10 th Nov 06 Presentation 1 Introduction Contents Global Tuberculosis Scenario Burden of Tuberculosis.
Revised National Tuberculosis Control Programme (RNTCP)
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
NGO-Collaboration: lessons learned and way forward Faruque Ahmed Director, Health and Nutrition Program BRAC.
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
RNTCP: DOTS Expansion and plans for DOTS-Plus
Challenge 4: Linking TB & HIV/AIDS Programs Kayt Erdahl, Project HOPE Rodrick Nalikungwi, Project HOPE Malawi December 18, 2008.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Activities in Project Axshya (GFR 9 TB project)
Mongolia Progress Report Dr. D. Otgontsetseg, Head of recording and reporting unit, TB surveillance and research department, NCCD The ninth Technical Advisory.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Action Plan Good Health Situation of Population in Capital of Myanmar Yangon Division By DR MYA THIDA AYE.
Monitoring and Evaluation in MCH Programs and Projects MCH in Developing Countries Feb 10, 2011.
Monitoring and Evaluation Module 12 – March 2010.
1 Module OVERVIEW OF EXTERNAL QUALITY ASSESSMENT.
Unit 10. Monitoring and evaluation
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
Monitoring, supervision and quality control IDSP training module for state and district surveillance officers Module 11.
Japan Dr. Ismail M. Aboshama Zidan Surveillance Coordinator of NTP-Egypt Action Plan to Strengthen Laboratory Diagnostic.
B.L.TEJASWI INTERN JJMMC. Which is the biggest disease today ?????
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Drug Resistance Pattern of Tuberculosis in India- Status Report Tuberculosis Research centre (ICMR)
Monitoring Process of the National TB Control Program (NTP) in the Philippines Anna Marie Celina G. Garfin, MD Medical Specialist IV National Center for.
NATIONAL TB 2012 INDICATOR ANALYSIS REPORT Presented by: Sandile Ginindza Lugogo Sun Hotel 05 th -7 th June 2013 Ministry of Health NTCP.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
National Tuberculosis Control Program in Bangladesh : Progress Report Dr. Shamim Sultana Deputy Programme Manager, TB National TB Control Programme.
Contribution of operational research in China National Center for TB Control and Prevention, China CDC Jiang Shiwen Cancun.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Global Fund Grant Proposal Round 11: Tuberculosis Nathan Furukawa Gabriella Boyle Rebekah Miner Paa Kobina Forson Xiaoxue Huang Hunter Pugh Gap Analysis.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Challenges and Constraints for TB Control in Kenya Dr. James Nyikal Director of Medical Services, Kenya.
Stop TB in China Challenges, Constraints & Actions Dr Wang Longde Vice Minister of Health China 24 March 2004.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Strengthening TB and HIV&AIDS Responses in East Central Uganda Strengthening Laboratory TB diagnostic capacity of peripheral laboratories in East Central.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
Dr. Somil Nagpal, ICAS MBBS, MHA, MBA, F. I. I. I
TB- HIV Collaborative activities in Romania- may 2006 status
Summary of changes in the RNTCP technical guidelines in
TB/HIV surveillance : Who is going to get the job done?
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Key issues in DOTS implementation
Objectives of Session Provide an overview of the development of Compendium Explain the organization of the Compendium and how indicators are used Provide.
The role of the community in TB control
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
South Africa: From ProTest to Nationwide Implementation
From ProTEST to Nationwide Implementation
The STOP TB Strategy – 2009 VISION: A TB-free world
Current status – (1) Achievements Building strong political commitment
Presentation transcript:

Monitoring & Evaluation of RNTCP Dr Rajeswari Ramachandran Retd. Dy. Director (Sr Gr) Tuberculosis Research Centre (ICMR) Chennai

Revised National TB Control Programme NTP in India since 1962 International evaluation done in 1992 Programme revised in 1993, adopting internationally accepted DOTS strategy RNTCP launched as a national programme in 1997 & rapid expansion of the programme started thereafter Entire country covered by March 2006

Objectives of RNTCP To achieve & maintain a cure rate of at least 85% among newly detected smear-positive pulmonary TB cases To achieve & maintain detection of at least 70% of such cases in the population

Features of RNTCP Creation of sub-district unit for every 500,000 population (TU) Supervisory staff at Sub-district level Modular participatory training for the staff at all level Establishing microscopy center for every 100000 popn. (DMC) Establishment of QA system (sputum microscopy & drugs) TB register at the TU level Uniform recording & reporting system Decentralized service delivery with community participation Patient-wise drug boxes Regular monitoring of patient with DOT & smear microscopy

RNTCP Treatment Regimens 2H3R3Z3 / 4H3R3 New smear negative and extra-pulmonary, not seriously ill Cat III 2H3R3Z3E3S3 / 1H3R3Z3E3 / 5H3R3E3 Previously treated smear positive (relapse, failure, treatment after default) Cat II 2H3R3Z3E3 / 4H3R3 New smear positive; seriously ill smear negative; seriously ill extra-pulmonary Cat I Note: Any patient, pulmonary or extra-pulmonary, who is known to be HIV positive based on voluntary sharing of results and/or history of ART, is considered as seriously ill. Such patient should get Cat-I treatment (if new), or Cat-II treatment (if previously treated)

Programme Monitoring RNTCP monitoring strategy is based on: Supervision: fixed no. of days for different staff and standard checklists Review meetings: using standard indicators and checklists Internal evaluation: 2 disticts per month per state using standard protocol Monitoring indicators: Exhaustive list of indicators for all levels of monitoringr

Key programme monitoring indicators TB suspects / chest symptomatics (subjects with cough >2 weeks) examined for sputum examination Proportion of symptomatics with positive smear New smear positive case detection rate Proportion of smear positive out of total new PTB cases Proportion of diagnosed smear-positive patients who were initiated on treatment Smear conversion at the end of 2/3 months of treatment Treatment outcome at the end of treatment

Programme Surveillance System Peripheral Health Institute Monthly Report Tuberculosis Unit System electronic from district level upwards Quarterly Report Quarterly Feedback Quarterly Feedback District TB Centre Quarterly Report State TB Cell Central TB Division

Key achievements of RNTCP Achievements in line with the global targets Full country coverage 450 Million population coverage Treatment success has recently exceeded the global target of 85% Case Detection in DOTS areas has recently attained global target of 70% Since implementation >48 million TB suspects examined >13 million pts placed on treatment >2.3 million lives saved Achievements in line with the global targets 9

Treatment outcome of smear positive cases registered under DOTS 4Q 2009 New sm + cases (N=143852) Re Rx cases (N=25443)

What is evaluation? “Systematic collection of information about the activities, characteristics & outcomes of programs”

Why do we need to evaluate? Programme evaluation helps to: assess the programme performance make judgments about the program improve program effectiveness and/or inform decisions about future program development Evaluations should be done at regular intervals

When do we evaluate Evaluations should be done at regular intervals In India, RNTCP evaluation is being done at three levels Inter-district evaluations by the state at quarterly intervals (2 districts each quarter) External evaluation by a central team (>2 districts each quarter) International evaluation at 3-yearly interval

What to evaluate Evaluation should include the important indicators for the programme Whether the processes are in place Whether outputs, in terms of patients detected & cured, are meeting the benchmarks Impact evaluation

Evaluation of RNTCP Process & outcome evaluation Impact evaluation Evaluation by funding agencies

Issues to be looked into during evaluation Organization of TB services in the State Political & administrative commitment Capacity of the State TB Cell (STC) in programme monitoring Capacity of the STC in financial monitoring Human resources Drug management system Involvement of other health sectors (public & private) Assess Advocacy Communication Social Mobilization (ACSM) activities Standard programme monitoring indicators TB/HIV activities Intermediate Ref. Laboratory (IRL) & management of MDR-TB Any other issues

Process Evaluation of RNTCP Being done at different levels: Evaluation at review meetings at district & state levels Internal evaluation Those conducted by states Those by CTD External evaluation (Joint Monitoring Mission at a frequency of 3 years)

Regular Evaluation Performance indicators are monitored & evaluated at: The sub-district level through monthly meetings at district level District level through quarterly meetings at state level with DTOs State level by the center every 6 months Quarterly reports are regularly published on the website (tbcindia.org)

Internal evaluation by the State Each state select 2-districts based on performance (one good & one bad performing district) Evaluation done by another district DTO & RNTCP consultant (4 days) STO is a member of the team Report & recommendations sent to central TB division & STO Corrective actions taken checked at next quarterly review

Central level internal evaluation One state each month, standardized forms used for data collection & reporting Purposive sampling of 2-districts 5 DMCs: one at the DTC, 4 randomly selected, additionally one DMC (medical college/NGO/Private/tribal/urban slum) Visit all the DOT centers in the DMC area & 3 more in the district with unique characteristics Visit 5 NSP cases (randomly selected) in each of the 5 DMCs Visit 2 pts. (not NSP) from the DOT centers at DTC & TU level Visit at least 3 pediatric patients Review state level issues

Central level internal evaluation Oral feed back to the local staff during visit Apprise DTO on salient observations at the end of IE Communicate salient observations & recommendations with state officials (DHO & Secretary, Health) Submit the summary evaluation report to central TB division & state authorities

Central level internal evaluation Central evaluation helps to: Identify factors leading to good performance, that could be replicated Analyse reasons for poor performance to take corrective action Ultimate aim being to improve performance Action taken on recommendations to be submitted

External evaluation Referred to as Joint Monitoring Mission Conducted once in 3-years 4 reviews conducted so far: 2000, 2003, 2006 & 2009 National & international experts from various organizations

Issues identified by JMM 2006 Rapid expansion outpacing the management capacity Weak general health system Frequent transfers of trained staff Dependence on external technical & financial assistance Quality of DOT ? Promoting drug resistant TB Lack of quality assured culture/drug susceptibility testing facilities Wide prescription of second line drugs ? Promoting XDR TB Inadequate involvement of private sector including medical colleges Limited availability of decentralised HIV testing TB HIV collaborative activities pose burden on TB programme managers Implementing infection control Implementing ACSM activities

JMM Recommendations India 2009

Main Recommendations Political commitment, management & health system strengthening In line with the Stop TB Strategy, GoI & RNTCP to aim to achieve universal access for all forms of TB, going well beyond the 2005 targets of at least 70% CDR & 85% treatment success. To mobilize greater resources (both financial & human) & in underperforming states & districts, to enhance political & administrative commitment & improve supervision & monitoring Review the financial requirements & commitments for the period 2010 to 2015, including those of GoI & external sources, to ensure that sufficient resources are available for the expected dramatic increase in costs for the planned MDR-TB management scale up & for meeting the 2015 TB-related targets. To leverage the increasing GoI commitment to health financing to meet the increasing financial needs of the TB programme.

Impact evaluation Repeat community based survey in a rural area of Tamilnadu, TRC, Chennai Two ARTI survey completed disease prevalence surveys at 5 sentinel sites Drug Resistance Surveillance

ARTI survey A nation wide survey to estimate ARTI was conducted & the ARTI for the year 2000 was estimated to be 1.5% with zonal variation Repeat survey has been completed

Sentinel surveillance Six sites have been identified for sentinel surveillance of the prevalence of disease survey to be done at periodic intervals First round of survey has been completed

Drug resistance surveillance TRC has been monitoring DRS in the project area among patients admitted for treatment Initial surveillance has been carried out in two states Plans to be done in more states

Donor evaluations External funding for the RNTCP World bank: >60% of RNTCP USAID: Haryana GFATM: AP, Chhattisgarh, Jharkand, Uttaranchal, Orissa & parts of Bihar and UP DFID: For drugs through GDF/WHO (almost half of the drug requirement of RNTCP supplied by DFID) Donor evaluations on financing and HR once in 6m / one year

Summary RNTCP Internal Evaluation helps to take corrective actions Regular monitoring and inbuilt process evaluations helped the programme implementation Baselines were not available so Impact Evaluations were planned few years before

Thank You